Gongwin Biopharm Holdings Co., Ltd.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

www.gongwinbiopharm.com

Country

Taiwan

Exchange

Taipei Exchange

Founded 2014

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer.

Its portfolio also includes PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma, PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma, and PTS500 for the treatment of malignant pleural effusion.

It also develops animal medicines. Its portfolio also includes engaged in the pet medical business, and wholesale and retail of the medical equipment. Founded in 2014, Gongwin Biopharm is based in Taipei, Taiwan.

Key Stats

52-Week Range

NT$58.30NT$120.00

Beta0.25

Trailing P/EN/A

Forward P/EN/A

Trailing EPS-0.92

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.